← Japan catalog ← 4502 Manual 4506 → ← 4502 Pharmaceuticals 4506 →
4503 · Astellas Pharma
This is a quantitative scorecard. The numbers below are read directly from Astellas Pharma’s EDINET filing, in yen. The Japanese-language narrative, what the business does, its risks, what changed this year, is not machine-read here, so we do not paraphrase it. Find it on EDINET (code 4503) →
The record
What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.
The record, 2017–2026
realized figures from each filing · older years to the left| 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | 2026’26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| ¥1.31T | ¥1.30T | ¥1.31T | ¥1.30T | ¥1.25T | ¥1.30T | ¥1.52T | ¥1.60T | ¥1.91T | ¥2.14T | RevenueRevenue |
| — | — | — | ¥1.02T | ¥1.00T | — | — | — | ¥1.56T | ¥1.73T | Gross profitGross prof. |
| — | — | — | 79% | 80% | — | — | — | 82% | 81% | Gross marginGross mgn |
| — | — | — | 38% | 40% | — | — | — | 44% | 40% | SG&A / revenueSG&A/rev |
| — | — | — | 13% | 11% | — | — | — | 9% | 8% | R&D / revenueR&D/rev |
| ¥15.6B | ¥213.3B | ¥243.9B | ¥244.0B | ¥136.1B | ¥155.7B | ¥133.0B | ¥25.5B | ¥41.0B | ¥382.6B | Operating incomeOp. inc. |
| 1.2% | 16.4% | 18.7% | 18.8% | 10.9% | 12.0% | 8.8% | 1.6% | 2.1% | 17.9% | Operating marginOp. mgn |
| ¥218.7B | ¥164.7B | ¥222.3B | ¥195.4B | ¥120.6B | ¥124.1B | ¥98.7B | ¥17.0B | ¥50.7B | ¥291.5B | Net incomeNet inc. |
| Cash flow & returns | ||||||||||
| ¥235.6B | ¥312.6B | ¥258.6B | ¥222.0B | ¥306.8B | ¥257.4B | ¥327.8B | ¥172.5B | ¥194.5B | ¥560.2B | Operating cash flowOp. cash |
| ¥16.9B | ¥147.9B | ¥36.4B | ¥26.6B | ¥186.3B | ¥133.4B | ¥229.1B | ¥155.4B | ¥143.8B | ¥268.7B | Working capital & otherWC & other |
| — | ¥25.1B | ¥25.2B | ¥41.3B | ¥31.4B | ¥30.7B | ¥36.4B | ¥38.1B | ¥37.0B | ¥57.7B | CapexCapex |
| — | 1.9% | 1.9% | 3.2% | 2.5% | 2.4% | 2.4% | 2.4% | 1.9% | 2.7% | Capex / revenueCapex/rev |
| — | ¥287.5B | ¥233.4B | ¥180.7B | ¥275.5B | ¥226.7B | ¥291.3B | ¥134.4B | ¥157.5B | ¥502.5B | Owner earningsOwner earn. |
| — | 22.1% | 17.9% | 13.9% | 22.0% | 17.5% | 19.2% | 8.4% | 8.2% | 23.5% | Owner earnings marginOE mgn |
| — | ¥287.5B | ¥233.4B | ¥180.7B | ¥275.5B | ¥226.7B | ¥291.3B | ¥134.4B | ¥157.5B | ¥502.5B | Free cash flowFCF |
| — | 22.1% | 17.9% | 13.9% | 22.0% | 17.5% | 19.2% | 8.4% | 8.2% | 23.5% | Free cash flow marginFCF mgn |
| ¥70.1B | ¥71.7B | ¥72.1B | ¥73.6B | ¥76.3B | ¥85.6B | ¥100.9B | ¥117.6B | ¥130.3B | ¥137.5B | Dividends paidDiv. paid |
| ¥92.2B | ¥130.7B | ¥160.4B | ¥52.9B | ¥9.2B | ¥50.7B | ¥60.6B | ¥10.7B | ¥7.0B | ¥730M | BuybacksBuybacks |
| 1% | 13% | 14% | 15% | 8% | 9% | 8% | 1% | 2% | 14% | ROICROIC |
| 17% | 13% | 18% | 15% | 9% | 8% | 7% | 1% | 3% | 16% | Return on equityROE |
| 12% | 7% | 12% | 9% | 3% | 3% | −0% | −6% | −5% | 8% | Retained to equityRetained/eq |
| Balance sheet | ||||||||||
| ¥96.8B | ¥331.7B | ¥311.1B | ¥320.4B | ¥326.1B | ¥316.0B | ¥376.8B | ¥335.7B | ¥188.4B | ¥281.6B | Cash & investmentsCash+inv |
| ¥169.6B | ¥25.3B | ¥189.8B | ¥158.6B | ¥149.8B | ¥146.2B | ¥148.7B | ¥194.7B | ¥194.4B | ¥234.1B | ReceivablesReceiv. |
| ¥97.5B | ¥54.0B | ¥55.1B | ¥49.0B | ¥45.9B | ¥28.5B | ¥50.7B | ¥61.4B | ¥75.5B | ¥70.0B | InventoryInvent. |
| ¥267.2B | ¥79.3B | ¥244.9B | ¥207.6B | ¥195.7B | ¥174.7B | ¥199.4B | ¥256.1B | ¥269.9B | ¥304.1B | Operating working capitalOper. WC |
| ¥481.0B | ¥845.6B | ¥857.2B | ¥867.5B | ¥872.6B | ¥923.4B | ¥1.05T | ¥1.19T | ¥1.20T | ¥1.42T | Current assetsCur. assets |
| ¥572.7B | ¥538.7B | ¥650.1B | ¥653.4B | ¥476.5B | ¥505.4B | ¥405.6B | ¥856.5B | ¥626.5B | ¥717.0B | Current liabilitiesCur. liab. |
| 0.8× | 1.6× | 1.3× | 1.3× | 1.8× | 1.8× | 2.6× | 1.4× | 1.9× | 2.0× | Current ratioCurr. ratio |
| — | ¥213.0B | ¥225.9B | ¥278.3B | ¥284.0B | ¥303.0B | ¥328.4B | ¥418.7B | ¥415.2B | ¥441.2B | GoodwillGoodwill |
| ¥1.81T | ¥1.86T | ¥1.90T | ¥2.32T | ¥2.27T | ¥2.33T | ¥2.46T | ¥3.57T | ¥3.34T | ¥3.57T | Total assetsAssets |
| ¥379.7B | ¥367.9B | ¥445.7B | ¥288.0B | ¥317.2B | ¥224.4B | ¥125.0B | ¥920.0B | ¥831.4B | ¥566.0B | Total debtDebt |
| ¥282.9B | ¥36.2B | ¥134.6B | (¥32.4B) | (¥8.9B) | (¥91.6B) | (¥251.8B) | ¥584.3B | ¥643.1B | ¥284.3B | Net debt / (cash)Net debt |
| 11.9× | 119.7× | 354.0× | 109.3× | 64.2× | 67.3× | 41.4× | 3.4× | 2.9× | 37.1× | Interest coverageInt. cov. |
| ¥1.27T | ¥1.27T | ¥1.26T | ¥1.29T | ¥1.39T | ¥1.46T | ¥1.51T | ¥1.60T | ¥1.51T | ¥1.83T | Shareholders’ equityEquity |
| Per share | ||||||||||
| 2.15B | 2.07B | 1.98B | 1.86B | 1.86B | 1.84B | 1.81B | 1.81B | 1.81B | 1.81B | Shares out (diluted)Shares |
| ¥608.99 | ¥628.53 | ¥659.83 | ¥698.71 | ¥671.14 | ¥706.03 | ¥839.17 | ¥886.17 | ¥1056.73 | ¥1182.12 | Revenue / shareRev/sh |
| ¥101.54 | ¥79.60 | ¥112.27 | ¥104.96 | ¥64.77 | ¥67.59 | ¥54.55 | ¥9.42 | ¥28.04 | ¥161.10 | EPS (diluted)EPS |
| — | ¥138.99 | ¥117.91 | ¥97.07 | ¥147.95 | ¥123.49 | ¥160.98 | ¥74.28 | ¥87.04 | ¥277.66 | Owner earnings / shareOE/sh |
| — | ¥138.99 | ¥117.91 | ¥97.07 | ¥147.95 | ¥123.49 | ¥160.98 | ¥74.28 | ¥87.04 | ¥277.66 | Free cash flow / shareFCF/sh |
| ¥32.57 | ¥34.64 | ¥36.42 | ¥39.53 | ¥40.97 | ¥46.62 | ¥55.77 | ¥64.97 | ¥71.98 | ¥75.98 | Dividends / shareDiv/sh |
| — | ¥12.12 | ¥12.72 | ¥22.17 | ¥16.86 | ¥16.74 | ¥20.14 | ¥21.03 | ¥20.45 | ¥31.90 | Cap. spending / shareCapex/sh |
| ¥590.49 | ¥613.05 | ¥635.61 | ¥692.44 | ¥744.51 | ¥795.44 | ¥833.28 | ¥881.93 | ¥836.21 | ¥1010.71 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +7.6%/yr | +12.0%/yr |
| Owner earnings / share | +9.0%/yr (8-yr) | +13.4%/yr |
| EPS | +5.3%/yr | +20.0%/yr |
| Dividends / share | +9.9%/yr | +13.1%/yr |
| Capital spending / share | +12.9%/yr (8-yr) | +13.6%/yr |
| Book value / share | +6.2%/yr | +6.3%/yr |
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2026 the business turned ¥291.5B of profit into ¥502.5B of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Reported net income | ¥291.5B | ¥50.7B | ¥17.0B | ¥98.7B | ¥124.1B |
| Working capital & othertiming of cash in and out, other non-cash items | +¥268.7B | +¥143.8B | +¥155.4B | +¥229.1B | +¥133.4B |
| Cash from operations | ¥560.2B | ¥194.5B | ¥172.5B | ¥327.8B | ¥257.4B |
| Capital expenditurecash put back in to keep running and to grow | −¥57.7B | −¥37.0B | −¥38.1B | −¥36.4B | −¥30.7B |
| Owner earnings | ¥502.5B | ¥157.5B | ¥134.4B | ¥291.3B | ¥226.7B |
| Owner-earnings marginowner earnings ÷ revenue | 23% | 8% | 8% | 19% | 17% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries Limited | $17.3B | 48% | -2.2% | -2% | 6% |
| 4578Otsuka Holdings | $15.6B | 70%4y | 9.5% | 6% | 11% |
| REGNRegeneron Pharmaceuticals Inc. | $14.3B | 96%2y | 34.6% | 21% | 31% |
| VTRSViatris | $14.3B | 35% | 2.5% | 0% | 14% |
| NVSNovartis AG | $14.0B | — | 126.2%1y | — | 126%1y |
| 4503Astellas Pharma | $13.5B | 81%4y | 11.4% | 9% | 18% |
| 4568Daiichi Sankyo | $13.4B | 67%4y | 9.2% | 8% | 7% |
| VRTXVertex Pharmaceuticals Incorporated | $12.0B | 87% | 31.8% | 36% | 34% |
| Group median | — | 70% | 10.5% | 8% | 16% |
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 37.1×ComfortableOperating income ¥382.6B ÷ interest expense ¥10.3B
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? ¥284.3B · 0.7× operating profitModest net debtCash ¥281.6B − debt ¥566.0B
What this means
Netting ¥281.6B of cash and short-term investments against ¥566.0B of debt leaves ¥284.3B owed, about 0.7× a year's operating profit (1.5× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Solid through the cycle10-yr median, range 1%–15%; 14% latest = NOPAT ¥302.3B ÷ invested capital ¥2.11TIndustry peers: median 17%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 14% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle9-yr median margin, range 8%–23%; latest ¥502.5B = operating cash ¥560.2B − maintenance capex ¥57.7BIndustry peers: median 14%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 23% of revenue this year, a 18% median across 9 years.
- Cash-backedCash from ops ¥560.2B ÷ net income ¥291.5B
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Reinvests most of itDividends + buybacks ¥138.2B ÷ Owner Earnings ¥502.5B — this fiscal year
What this means
Of ¥502.5B Owner Earnings, ¥138.2B (28%) went back to shareholders, ¥137.5B dividends, ¥730M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does. This year's proportion is 28%; across the record (2018–2026) it is 59%, the capital-allocation section below.
- Investing or harvesting? —Not enough data
What this means
The filing data didn't include the inputs for this check.
Durability & moat, 2017–2026
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 10 of 10
What this means
Never lost money over the record, the earnings stability Graham insisted on.
- Return on capital ≥ 15% 1 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 12% → 7% (3-yr avg ends)
What this means
The recent-years average (7%) sits below the early years (12%), but the latest year (18%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 11% — read it across the cycle, not on the dip.
- Reinvestment, incremental ROIC −1%
What this means
Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.
- Owner earnings growth +3%/yr
What this means
Owner earnings grew about 3% a year over the record.
- Worst year 2017 · 1.2% op. margin
What this means
Stayed profitable even in its hardest year, the resilience that survives recessions.
- Share count −1.9%/yr
What this means
The share count is shrinking, buybacks are quietly growing your slice of the business.
- Dividend record rising
What this means
Paid and raised the dividend across the record, the continuity Graham prized.
All figures as filed; the source filing is linked above.
How the cash was used, 2018–2026
Over the record, the business generated ¥2.61T of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested¥322.9B · 12%
- Dividends¥865.5B · 33%
- Buybacks¥482.9B · 18%
- Retained (debt / cash)¥941.2B · 36%
- Returned to owners¥1.35T
59% of the owner earnings the business produced over the span, ¥865.5B as dividends and ¥482.9B as buybacks.
- Average price paid for buybacks—
Buybacks ran ¥482.9B over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count−12.5%
The diluted count fell from 2069M to 1810M, so the buybacks outran the stock issued to staff.
- Dividend record¥75.98/sh
Paid in 9 of the years on record, the per-share dividend growing about 10% a year. It was never cut over the span.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
The price
What a price would have to assume, set against the record above.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Astellas Pharma has delivered.
Astellas Pharma’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Astellas Pharma earns about ¥382.3B on its 17.9% median owner-earnings margin. This year’s 23.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings ¥502.5B on 1810M diluted shares; net debt ¥284.3B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.
Manual order: ← 4502 its page in the Manual 4506 →
Industry order: ← 4502 the Pharmaceuticals chapter 4506 →